Table 1.
Background for COVID-19 patents treated with FPV (n = 27).
| Variables | number or median | (% or IQR) |
|---|---|---|
| Gender－no./total no. (%) | ||
| Male | 17/27 | (63.0) |
| Female | 10/27 | (37.0) |
| Median age (IQR) －yr | 63 | (49, 85) |
| Severity of COVID-19－no./total no. (%) | ||
| Mild | 6/27 | (22.2) |
| Moderate | 19/27 | (70.4) |
| Severe | 2/27 | (7.4) |
| Comorbidity－no./total no. (%) | 13/27 | (48.1) |
| Blood levels－median (IQR) | ||
| FPV (μg/mL) | 42.1 | (22.3, 85.5) |
| WBC (/μL) | 5400 | (4300, 6100) |
| ALT (U/L) | 21 | (13, 34) |
| LDH (U/L) | 217 | (181, 265) |
| CRP (mg/dL) | 1.2 | (0.7, 7.7) |
| Ferritin (ng/mL) | 242.1 | (177.5, 835.3) |
| D-dimer (μg/mL) | 0.5 | (0.2, 1.3) |
| Uric acid (mg/dL) | 5.0 | (4.5, 5.7) |
| eGFR (mL/min/1.73m2)－median (IQR) | 67.2 | (59.0, 84.0) |
Data are presented as number (%) or median (interquartile range; IQR).
Blood FPV levels were calculated as the mean trough level after reaching a steady-state of FPV.